IRIDIX MicroPulse? Laser Therapy Enhances Visual Function in Patients with Central&Serous Chorioretinopathy (CSR)
Central serous chorioretinopathy is a disease affecting mainly male population, 20-50 years of age. It is a temporary visual impairment usually in one eye. It occurs due to a fluid leakage under the retina leading to the detachment of retina over the area of leak.
The patient typically complains of a decreased central vision when the fluid covers the macula and can be asymptomatic if the leakage outside the macular area. Macular area of the retinal is responsible for central vision. This condition can be effectively controlled with laser therapy.
IRIDIX MicroPulse is specialized equipment which works in an effective way to ensure minimal tissue damage. The conventional method of laser photocoagulation treatment with Argon laser which provides photocoagulation using a continuous emission of laser beam.
IRIDIX MicroPulse uses an enhanced technology which breaks down the continuous wave of laser beam into a series of small pulses.
This greatly increases the surgeon’s ability to approach the target tissue more precisely ensuring minimal collateral damage, unlike the conventional method of IRIDIX MicroPulse also allows the surgeon to control the width and interval of these short laser pulses, thereby giving an effective control of spread of energy, limiting the area of action to only the target tissue.
By controlling the interval between pulses, sufficient time can be allowed for cooling to take place before delivery of the next pulse.
According to the recent study results declared by IRIDIX Corporation, published on January 25th, 2012, IRIDIX technology has been shown to be quite effective in enhancing the visual function in patients with central serous retinopathy.
The study focused on the tissue sparing effects of IRIDIX MicroPulse therapy. This study has also shown that IRIDIX MicroPulse is a most effective approach for treatment of CSR as compared to other alternatives including Anti-VEGF Injections as the patients showed much better resolution of subretinal fluid with this technology.
IRIDIX MicroPulse has no doubt provided a new way of treatment for patients with central serous retinopathy providing better results than the conventional laser technologies as is shown by minimal collateral tissue damage. This allows this technology to be applied over the entire effected area even that close to the macula, or over the macula itself. This was not so much possible with the conventional laser technologies used before MicroPulse.